Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
accrual, analyze, appeal, arguing, artificial, attack, biotherapeutic, broker, brokerage, Cantor, capsule, Carnegie, cell, CERT, Chamber, chronic, CIN, Climacteric, commerce, Connecticut, construction, consummation, deadline, decade, deceptive, deletion, deviation, DSM, dysplasia, East, Edition, element, embarrassment, embodying, encompassed, Endeavour, ERM, Erroneously, evenly, evidencing, Fitzgerald, Florida, FTC, geared, gelatin, gene, GSM, guilt, Hard, Haskell, hoc, HPV, idiopathic, IIb, impartial, Indiana, intelligence, Interagency, intraepithelial, Iowa, IRR, legitimate, lender, lien, lifestyle, LLP, lopinavir, Manchester, Manual, MARDEE, Mellon, Mental, Montana, neoplasia, odd, opposed, Oregon, orgasm, pad, peak, Pearl, pharmacodynamic, polarization, pronounced, protein, provisional, questionnaire, reclassified, Recovery, repaid, rescue, ritonavir, round, sensation, situation, soft, South, Stifel, stronger, strongly, subgroup, successor, symptomatic, Tennessee, Text, TR, underdiagnosed, unearned, unexercised, unfair, unitary, UPC, Utah, VMI
Filing tables
Filing exhibits
Related press release
DARE similar filings
Filing view
External links
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-3 (File Nos. 333-254862 and 333-238299) and Form S-8 (File Nos. 333-264020, 333-266699, 333-254864, 333-237473, 333-230802, 333-226904, 333-211697, 333-204007, and 333-198126) of our report dated March 30, 2023, with respect to our audit of the consolidated financial statements of Daré Bioscience, Inc. and Subsidiaries (Company) as of and for the year ended December 31, 2022 (which includes an explanatory paragraph relating to the uncertainty of the Company’s ability to continue as a going concern), which report is included in this Annual Report on Form 10-K.
/s/ Mayer Hoffman McCann P.C.
San Diego, California
March 28, 2024